Ethics and Social Implications of Biotechnology

Q1 — Sample Band 6 response (7 marks), annotated

Ethical use of biotechnology is judgement of a technology against values such as welfare, fairness, autonomy, ownership and environmental responsibility, performed by analysing how the technology affects each relevant stakeholder. [1 — definition + stakeholder link]

Both plant and animal biotechnology share three of the lesson's four criteria — food security/benefit, ownership, equity and environmental effect — but they differ sharply on the welfare criterion. Plant biotechnology can deliver benefits such as improved yield, drought tolerance or vitamin enrichment (e.g. Bt cotton's pesticide reduction, Golden Rice's β-carotene fortification, glyphosate-resistant soy's labour efficiency). Its central ethical concerns sit on the ownership and environment criteria: patented seed (Roundup Ready soy) creates farmer dependence on a small number of agribusiness suppliers, gene flow can erode wild crop biodiversity, and reduced agricultural diversity can amplify the impact of new pests. [1 — at least one named plant example with criterion]

Animal biotechnology can deliver disease-resistance, productivity, or biomedical use (e.g. GloFish bred for fluorescence; AquAdvantage transgenic salmon engineered for faster growth; recombinant-bovine-somatotropin-treated dairy cattle; the OncoMouse used in cancer research). Animal cases share all the same plant-side concerns about ownership and environment — but in addition the modified organism can directly experience suffering. Transgenic salmon raise welfare concerns through escape risk and possibly poorer health phenotypes; rBST-treated dairy cattle have documented increases in mastitis and lameness; the OncoMouse is engineered specifically to develop tumours. The welfare criterion is therefore engaged in a way it is not engaged in plant biotechnology. [1 — at least one named animal example with criterion]

Comparing on three explicit criteria: welfare — animal biotechnology engages this criterion directly because animals are sentient; plant biotechnology does not raise welfare in the same direct sense. Ownership / equity — both domains raise concerns about patented genetic material and concentration of corporate control (Monsanto's seed patents; large biotech firms' control of transgenic animals), but ownership in plants more directly affects food security and farmer livelihoods, while ownership in animals more directly affects research access and veterinary practice. Environment — both engage this criterion, but the failure modes differ: GM crop escape into wild relatives versus transgenic-animal escape into wild populations (salmon being the textbook case). [1 — first comparison criterion] [1 — second comparison criterion] [1 — third comparison criterion]

Neither domain is universally more ethical: each must be judged in context. Plant biotechnology raises sharper concern where ownership creates dependence and where ecological harm is concentrated (e.g. monoculture-driven biodiversity loss); animal biotechnology raises sharper concern where welfare is compromised for marginal productivity gain (e.g. rBST). The lesson's framework rejects a one-winner ranking — the central question is always who benefits, who bears the harm, and whether the harms are justified by the benefits. [1 — context-dependent judgement linked to stakeholder framework]

Marking criteria.

• 1 mark — Defines ethical use and links it to stakeholder analysis.
• 1 mark — Uses at least one valid named example of plant biotechnology (e.g. Bt cotton, Golden Rice, GM soy, Roundup Ready crops).
• 1 mark — Uses at least one valid named example of animal biotechnology (e.g. GloFish, AquAdvantage salmon, rBST dairy cattle, OncoMouse, transgenic livestock).
• 1 mark — Compares the two domains on the welfare criterion and explains why it is engaged more directly in animals.
• 1 mark — Compares the two domains on a second criterion (ownership, equity or food security).
• 1 mark — Compares the two domains on a third criterion (environment / biodiversity).
• 1 mark — Reaches an explicit context-dependent judgement that rejects a one-winner ranking and refers back to stakeholders / framework.

Q2 — Sample Band 6 response (8 marks), annotated

Position A (permissive with oversight) and Position B (restrictive moratorium) prioritise different stakeholders and different criteria from the lesson framework. [1 — frames as different stakeholder priorities] Position A centres the prospective parents and the future child with a serious heritable disease — its claim is that, with strict consent, oversight and access guarantees, heritable editing relieves an otherwise intractable welfare burden. Position B centres future generations, society at large, and communities at risk of inequity — its claim is that germline edits propagate, cannot be consented to by descendants, and risk normalising enhancement editing that would entrench biological inequity. [1 — identifies stakeholders prioritised by each side]

Comparing on welfare: Position A weighs immediate welfare benefit (preventing serious heritable disease) heavily and accepts residual technical risk under monitoring; Position B argues that off-target effects and unknown long-term phenotypes cannot be characterised against the welfare of unborn descendants. [1 — welfare comparison]

Comparing on consent: this is Position B's strongest leverage. Heritable edits cannot be consented to by future generations who carry them, and the lesson's consent criterion is therefore violated in a way that does not apply to somatic gene therapy. Position A responds that proxy consent (parental, regulatory) is acceptable for serious medical conditions, similar to other interventions in paediatric medicine. [1 — consent comparison]

Comparing on equity: Position A explicitly conditions permission on equitable access, but in practice CRISPR + IVF is expensive and unevenly distributed globally; Position B argues that without robust global equity guarantees, even therapeutic editing will entrench biological inequality between high- and low-income populations — a classic social implication concern in the lesson framework. [1 — equity comparison]

Comparing on ownership / regulatory risk: heritable editing tools are patented (e.g. CRISPR-Cas9 patent disputes), so commercial control of the technology is concentrated; Position B argues this concentrates decision-making power in a few private actors, while Position A argues that licensing and public-sector access can mitigate this. [1 — ownership / regulation comparison]

Both positions partly satisfy and partly fail the lesson's two-condition test for ethical acceptability (benefit weighed against harm; fair distribution of benefits and risks across stakeholders). Position A is defensible only if all four of its preconditions (independent ethics review, full informed consent, long-term monitoring, equitable access) are actually achieved — historically these are rarely all met. Position B is defensible only as long as no clinical case truly has no alternative reproductive option; once such a case exists, a blanket prohibition imposes its own welfare cost. [1 — applies framework to evaluate, not just describe]

My recommendation is a conditional version of A: a strictly limited therapeutic pathway only for serious heritable diseases where pre-implantation diagnosis cannot solve the case, gated by independent international oversight, with an explicit prohibition on non-medical enhancement and an active equity-of-access requirement. Where any one of these conditions cannot be guaranteed, position B becomes the default. This pairing tracks the lesson's central principle: ethical acceptability is environment-dependent, not technology-dependent. [1 — justified context-dependent recommendation in precise lesson terminology]

Marking criteria.

• 1 mark — Frames the two positions as prioritising different stakeholders, not as a debate about whether the technology works.
• 1 mark — Names at least two distinct stakeholder groups whose interests each position serves.
• 1 mark — Compares the two positions on the welfare criterion.
• 1 mark — Compares on the consent criterion (and shows why heritable editing engages it uniquely).
• 1 mark — Compares on the equity criterion (cost, distribution, social implication).
• 1 mark — Compares on at least one additional criterion (ownership, regulation, environment / heritable risk).
• 1 mark — Explicitly applies the lesson's framework (benefit vs harm + fairness across stakeholders) to evaluate, not merely describe, the positions.
• 1 mark — Reaches a justified, context-dependent recommendation in precise lesson terminology, rejecting the false binary.

Q3 — Sample Band 6 response (7 marks)

The editorial commits the central error the lesson warns against: it equates "scientifically safe + productive" with "ethically acceptable", and dismisses the rest of the ethical framework as sentiment. It also misrepresents specific facts about animal welfare and ownership. [1 — overall evaluative judgement]

Flaw 1 — "productivity + consumer safety alone." The lesson explicitly rejects this. Even if rBST is safe to consume and increases yield, ethical evaluation must also weigh welfare, ownership, equity and environmental effect. Productivity and consumer safety are two criteria out of at least five — the editorial collapses the framework to a subset. Correct framing: a biotechnology can be biochemically safe and economically beneficial and still be ethically problematic if other criteria are violated. [1 — identifies + corrects framework error]

Flaw 2 — "animal welfare arguments are sentimental, not scientific." This is factually wrong. Welfare in rBST-treated dairy cattle is well documented: rBST is associated with increased rates of mastitis (udder inflammation), reduced fertility and lameness — these are measurable veterinary outcomes, not sentiments. The lesson identifies animal welfare (suffering, stress, deformity, confinement) as a central ethical criterion in animal biotechnology precisely because the modified organism is sentient. Correct framing: welfare evidence is empirical, and the lesson treats it as a primary criterion in animal biotechnology, not a peripheral one. [1 — identifies + corrects welfare error]

Flaw 3 — "patent ownership has no bearing on ethical status." The lesson directly addresses this: patented biotechnology raises ownership and equity concerns because it concentrates economic benefit, can create farmer dependence, and may exclude smaller producers from accessing the technology. Whether or not rBST is safe, the question of who profits from its adoption and who is locked out is ethically relevant. Correct framing: ownership is an explicit lesson criterion, listed alongside welfare and environment, not a "political" add-on. [1 — identifies + corrects ownership error]

Flaw 4 (optional) — "if farmers don't adopt, they're falling behind." This commits the false-binary the lesson rejects: it presents the technology as a single-winner choice rather than a context-dependent decision. Whether rBST adoption is appropriate depends on the herd, the market (rBST is banned in the EU, Canada, Japan, New Zealand, Australia), and the welfare/economic trade-off in each context. Correct framing: ethical and commercial decisions are context-dependent. [1 — identifies + corrects false binary]

Defensible reformulation: "rBST increases milk yield by ~11–15% in treated dairy cows and is judged biochemically safe for human consumption by relevant regulators. However, ethical evaluation in animal biotechnology must also consider welfare (rBST is associated with increased mastitis, lameness and fertility issues), ownership (the technology is patented and concentrates economic benefit), equity (smaller producers and overseas markets that prohibit rBST), and environmental effects. Many jurisdictions including the EU, Canada, Japan, New Zealand and Australia have judged that the welfare and social costs outweigh the productivity benefit — rBST use is therefore best evaluated case-by-case, not as a productivity imperative." [1 — biologically defensible reformulation using framework]

Marking criteria.

• 1 mark — States an overall evaluative judgement of the editorial against the lesson framework.
• 1 mark — Identifies and corrects the central "safe + productive = ethical" error.
• 1 mark — Identifies and corrects the welfare-is-sentiment error with reference to measurable welfare indicators (e.g. mastitis, lameness, fertility) and the lesson's treatment of welfare.
• 1 mark — Identifies and corrects the "ownership doesn't matter" error using the lesson's ownership / equity criterion.
• 1 mark — Identifies the false-binary "must adopt or fall behind" framing and corrects it with the context-dependence principle.
• 1 mark — Uses precise lesson terminology (welfare, ownership, equity, environment, stakeholders, context) throughout.
• 1 mark — Provides a defensible reformulation that integrates all of the above and reaches a context-dependent verdict, not a one-winner ranking.